FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2899154313> ?p ?o ?g. }

• W2899154313 endingPage "899" @default.
• W2899154313 startingPage "890" @default.
• W2899154313 abstract "Tissue injury/hypoxia and oxidative stress induced-extracellular adenosine triphosphate (ATP) can act as damage-associated molecular pattern molecules, which initiate inflammatory response. Our objective was to elucidate the role of extracellular ATP in skin fibrosis in systemic sclerosis (SSc). We identified that hypoxia enhanced ATP release and that extracellular ATP enhanced IL-6 production more significantly in SSc fibroblasts than in normal fibroblasts. There were no significant differences of P2X and P2Y receptor expression levels between normal and SSc fibroblasts. Nonselective P2 receptor antagonist and selective P2Y2 receptor antagonists, kaempferol and AR-C118925XX, significantly inhibited ATP-induced IL-6 production and phosphorylation of p38 in SSc fibroblasts. ATP-induced IL-6 production was significantly inhibited by p38 inhibitors, SB203580, and doramapimod. Collagen type I production in SSc fibroblasts by ATP-induced IL-6/IL-6 receptor trans-signaling was inhibited by kaempferol and SB203580. The amount of ATP in bleomycin-treated skin was increased, and administration of AR-C118925XX significantly inhibited bleomycin-induced dermal fibrosis in mice. These results suggest that vasculopathy-induced hypoxia and oxidative stress might enhance ATP release in the dermis in SSc and that extracellular ATP-induced phosphorylation of p38 via P2Y2 receptor might enhance IL-6 and collagen type I production in SSc fibroblasts. P2Y2 receptor antagonist therapy could be a treatment for skin sclerosis in patients with SSc. Tissue injury/hypoxia and oxidative stress induced-extracellular adenosine triphosphate (ATP) can act as damage-associated molecular pattern molecules, which initiate inflammatory response. Our objective was to elucidate the role of extracellular ATP in skin fibrosis in systemic sclerosis (SSc). We identified that hypoxia enhanced ATP release and that extracellular ATP enhanced IL-6 production more significantly in SSc fibroblasts than in normal fibroblasts. There were no significant differences of P2X and P2Y receptor expression levels between normal and SSc fibroblasts. Nonselective P2 receptor antagonist and selective P2Y2 receptor antagonists, kaempferol and AR-C118925XX, significantly inhibited ATP-induced IL-6 production and phosphorylation of p38 in SSc fibroblasts. ATP-induced IL-6 production was significantly inhibited by p38 inhibitors, SB203580, and doramapimod. Collagen type I production in SSc fibroblasts by ATP-induced IL-6/IL-6 receptor trans-signaling was inhibited by kaempferol and SB203580. The amount of ATP in bleomycin-treated skin was increased, and administration of AR-C118925XX significantly inhibited bleomycin-induced dermal fibrosis in mice. These results suggest that vasculopathy-induced hypoxia and oxidative stress might enhance ATP release in the dermis in SSc and that extracellular ATP-induced phosphorylation of p38 via P2Y2 receptor might enhance IL-6 and collagen type I production in SSc fibroblasts. P2Y2 receptor antagonist therapy could be a treatment for skin sclerosis in patients with SSc." @default.
• W2899154313 created "2018-11-09" @default.
• W2899154313 creator A5017927991 @default.
• W2899154313 creator A5020166886 @default.
• W2899154313 creator A5020653698 @default.
• W2899154313 creator A5021287958 @default.
• W2899154313 creator A5030622546 @default.
• W2899154313 creator A5033190035 @default.
• W2899154313 creator A5043379248 @default.
• W2899154313 creator A5044927587 @default.
• W2899154313 creator A5067943705 @default.
• W2899154313 creator A5077813809 @default.
• W2899154313 creator A5081576859 @default.
• W2899154313 creator A5082094461 @default.
• W2899154313 date "2019-04-01" @default.
• W2899154313 modified "2023-10-05" @default.
• W2899154313 title "The Regulation of Skin Fibrosis in Systemic Sclerosis by Extracellular ATP via P2Y2 Purinergic Receptor" @default.
• W2899154313 cites W1490888491 @default.
• W2899154313 cites W1568069191 @default.
• W2899154313 cites W1964984352 @default.
• W2899154313 cites W1983512827 @default.
• W2899154313 cites W1984534675 @default.
• W2899154313 cites W1991073331 @default.
• W2899154313 cites W1999658138 @default.
• W2899154313 cites W2007476135 @default.
• W2899154313 cites W2030963075 @default.
• W2899154313 cites W2046492421 @default.
• W2899154313 cites W2049000251 @default.
• W2899154313 cites W2051670230 @default.
• W2899154313 cites W2057198431 @default.
• W2899154313 cites W2063879185 @default.
• W2899154313 cites W2066960334 @default.
• W2899154313 cites W2069166434 @default.
• W2899154313 cites W2069707834 @default.
• W2899154313 cites W2076527353 @default.
• W2899154313 cites W2082424235 @default.
• W2899154313 cites W2090346027 @default.
• W2899154313 cites W2096014264 @default.
• W2899154313 cites W2100700890 @default.
• W2899154313 cites W2100988335 @default.
• W2899154313 cites W2125874167 @default.
• W2899154313 cites W2127056262 @default.
• W2899154313 cites W2127438550 @default.
• W2899154313 cites W2129940663 @default.
• W2899154313 cites W2130372379 @default.
• W2899154313 cites W2136376193 @default.
• W2899154313 cites W2155231668 @default.
• W2899154313 cites W2159155074 @default.
• W2899154313 cites W2167645193 @default.
• W2899154313 cites W2347093301 @default.
• W2899154313 cites W2411779324 @default.
• W2899154313 cites W2498198862 @default.
• W2899154313 cites W2522959890 @default.
• W2899154313 cites W2729745157 @default.
• W2899154313 cites W2760109000 @default.
• W2899154313 cites W2799983009 @default.
• W2899154313 cites W4211001791 @default.
• W2899154313 doi "https://doi.org/10.1016/j.jid.2018.10.027" @default.
• W2899154313 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30404019" @default.
• W2899154313 hasPublicationYear "2019" @default.
• W2899154313 type Work @default.
• W2899154313 sameAs 2899154313 @default.
• W2899154313 citedByCount "20" @default.
• W2899154313 countsByYear W28991543132019 @default.
• W2899154313 countsByYear W28991543132020 @default.
• W2899154313 countsByYear W28991543132021 @default.
• W2899154313 countsByYear W28991543132022 @default.
• W2899154313 countsByYear W28991543132023 @default.
• W2899154313 crossrefType "journal-article" @default.
• W2899154313 hasAuthorship W2899154313A5017927991 @default.
• W2899154313 hasAuthorship W2899154313A5020166886 @default.
• W2899154313 hasAuthorship W2899154313A5020653698 @default.
• W2899154313 hasAuthorship W2899154313A5021287958 @default.
• W2899154313 hasAuthorship W2899154313A5030622546 @default.
• W2899154313 hasAuthorship W2899154313A5033190035 @default.
• W2899154313 hasAuthorship W2899154313A5043379248 @default.
• W2899154313 hasAuthorship W2899154313A5044927587 @default.
• W2899154313 hasAuthorship W2899154313A5067943705 @default.
• W2899154313 hasAuthorship W2899154313A5077813809 @default.
• W2899154313 hasAuthorship W2899154313A5081576859 @default.
• W2899154313 hasAuthorship W2899154313A5082094461 @default.
• W2899154313 hasBestOaLocation W28991543131 @default.
• W2899154313 hasConcept C126322002 @default.
• W2899154313 hasConcept C134018914 @default.
• W2899154313 hasConcept C160225129 @default.
• W2899154313 hasConcept C170493617 @default.
• W2899154313 hasConcept C172590197 @default.
• W2899154313 hasConcept C185592680 @default.
• W2899154313 hasConcept C2776151105 @default.
• W2899154313 hasConcept C2776885963 @default.
• W2899154313 hasConcept C2778122271 @default.
• W2899154313 hasConcept C2778938600 @default.
• W2899154313 hasConcept C2779564974 @default.
• W2899154313 hasConcept C2780410667 @default.
• W2899154313 hasConcept C2780559512 @default.
• W2899154313 hasConcept C28406088 @default.
• W2899154313 hasConcept C55493867 @default.
• W2899154313 hasConcept C57306754 @default.

• next